longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Arcutis Biotherapeutics

ARQT

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 115.21, above the reasonable range, cheaper than 0.54% of the time in the past 5 years, and the industry ranks 61/601, the industry Median -2.34.

115.21xP/E
$26.14Stock price
$0.23Earnings per share
115.21xP/E
Stock price$26.14Earnings per share$0.23

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-4.80x
Typical range
-14.65x–-2.57x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
PTGXUSProtagonist Therap
111.48x326.86%$9.24B
ALKSUSAlkermes
116.89x135.68%$7.73B
TLXUSTelix Pharmaceuticals
119.64x430.25%$4.01B
ARQTUSArcutis Biotherapeutics
115.21x409.23%$3.29B
MDXGUSMiMedx
110.64x153.13%$690.27M
ICCCUSImmuCell
110.85x--$87.28M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.